Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Submental Fat, Healthy
Interventions: ATX-101, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: San Diego, California • Englewood, Colorado • Coral Gables, Florida + 9 more

Conditions: Thyroid Neoplasms
Interventions: Sorafenib (Nexavar, BAY43-9006), Other Multikinase inhibitors; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 13 more

Conditions: Sickle Cell Disease
Interventions: Transfusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin

Conditions: Reperfusion Injury, Post Cardiac Arrest Brain Injury
Interventions: LUTICIA - Light Utilization COX-Inhibitory Device); Device
Lead sponsor: Mitovation, Inc; Industry
Eligibility: 48 Hours to 1 Year
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Hematopoietic Stem Cell Transplant, Atrial Fibrillation, Atrial Flutter
Interventions: HSCT Patients; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: Bevacizumab, Docetaxel, Oxaliplatin; Biological · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio

Conditions: Coronary Artery Disease, Coronary Arteriosclerosis
Interventions: Not listed
Lead sponsor: MDDX LLC; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: San Francisco, California • Bethesda, Maryland • Independence, Missouri

Conditions: Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Irinotecan, Leucovorin, Oxaliplatin, Capecitabine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 59 more

Conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: MIND1 System; Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Cerritos, California • Garden Grove, California • Oceanside, California + 3 more

Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions: CD371-specific/YSNVz/I-18 CAR T cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cerebrovascular Stroke, Depression
Interventions: Brief pleasurable events/behavioral therapy, Standard care; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arteriosclerosis
Interventions: clopidogrel (SR25990); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 45 Years and older
Enrollment: 15,603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Nocturia
Interventions: Compression stockings; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 110 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Chondromalacia Patella, Patellofemoral Pain Syndrome
Interventions: Synvisc-One™, Sham Treatment; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions: 64Cu-DOTA-ECL1i; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Kidney Injury, Fluid Overload, Ultrasonography
Interventions: Portal vein flow, Intra-renal flow, Hepatic vein flow, Pulmonary B-lines, Dimensions of the inferior vena cava, Left ventricular function, Right ventricular function; Diagnostic Test
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM); Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Depression, Anxiety, Opioid-Related Disorders, Pain, Chronic
Interventions: More Individualized Care: Assessment and Recovery through Engagement (MI-CARE); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Indianapolis, Indiana • Seattle, Washington

Conditions: Fertility Disorders
Interventions: CHLOE; Device
Lead sponsor: Fairtility; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Margate, Florida • Rochester, Minnesota

Conditions: Bioavailability
Interventions: Oxandrin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 55
States / cities: Phoenix, Arizona • Clovis, California • Duarte, California + 43 more

Conditions: Thrombotic Thrombocytopenic Purpura (TTP)
Interventions: TAK-755, Standard of care; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 0 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more

Conditions: Advance Care Planning, Primary Health Care
Interventions: ENACT group visit, Mailed Resources; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Aurora, Colorado • Boulder, Colorado • Denver, Colorado + 3 more

Conditions: Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions: Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim; Drug · Other · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Age of Blood in Sickle Cell Transfusion

Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.

Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Living Well With Stroke

Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Pathophysiologic Study to Understand and Possibly Treat Nocturia

Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury

More Individualized Care: Assessment and Recovery Through Engagement

Performance of CHLOE Algorithm on the Prediction of Blastocyst Formation

Oxandrolone in Healthy Adults: A Relative Bioavailability Study

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Effectiveness of Engaging in Advance Care Planning Talks (ENACT) Group Visits in Primary Care for Older Adults With and Without Alzheimer's Disease

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy